MedTrace Logo

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

NCT04842422 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-01-11

No results posted yet for this study

Summary

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream:

The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

Conditions

  • Actinic Keratoses

Interventions

DRUG

Imiquimod 3.75% Cream

Imiquimod 3.75% Cream

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2021-08-23
Completion
2021-08-23

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04842422 on ClinicalTrials.gov